Northern Trust Corp Has $2.68 Million Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)

Northern Trust Corp grew its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 2.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 269,597 shares of the company’s stock after purchasing an additional 7,678 shares during the period. Northern Trust Corp owned about 0.51% of Kodiak Sciences worth $2,682,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. The Manufacturers Life Insurance Company acquired a new position in shares of Kodiak Sciences during the 4th quarter worth approximately $902,000. Boothbay Fund Management LLC grew its position in shares of Kodiak Sciences by 22.0% during the 4th quarter. Boothbay Fund Management LLC now owns 157,858 shares of the company’s stock worth $1,571,000 after purchasing an additional 28,420 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $440,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $11,338,000. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Kodiak Sciences by 10,982.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company’s stock worth $12,622,000 after acquiring an additional 1,257,063 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating and set a $3.00 price target on shares of Kodiak Sciences in a research report on Monday, March 31st.

Kodiak Sciences Trading Down 3.1%

NASDAQ KOD opened at $3.44 on Friday. The firm has a market capitalization of $181.51 million, a price-to-earnings ratio of -0.94 and a beta of 2.42. The firm’s 50 day simple moving average is $3.30 and its 200 day simple moving average is $5.48. Kodiak Sciences Inc. has a 1 year low of $1.92 and a 1 year high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.20). On average, equities research analysts forecast that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.